β-catenin signaling mediates EGFR-TKI resistance in EGFR mutant NSCLC [35–37], and activation of β-catenin signaling pathway induces EGFR-TKI resistance in NSCLC cells [36–38]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.